MT -2766, the world's first plant-based COVID -19 vaccine candidate Application for approval was submitted in Canada.

December 17, 2021

Updated on December 17, 2021

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President: Hiroaki Ueno), an operating company of Mitsubishi Chemical Holdings Corporation (Head Office: Tokyo; President: Jean-Marc Gilson), announced today an application for approval in Canada for MT-2766, a COVID 19 vaccine candidate as follows.

Mitsubishi Tanabe Pharma Press Release